Cite

HARVARD Citation

    Zangardi, M. et al. (2017). Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Expert review of clinical pharmacology. 10 (11), pp. 1169-1176. [Online]. 
  
Back to record